CURX, +90.91% already, plus News Released!
|
StockRockandRoll Newsletter
[1]StockRockandRoll.com NEWSLETTER Members, CURX, +90.91% already, plus News Released! Symbol:CURX.pk Current PPS: $0.126 (+90.91%) High-of-the-Day PPS: $0.126 (+90.91%) Current Vol: 126.5K (Just 10-minutes into the day!) 10-Day Avg Vol: 55.4K Curaxis Pharmaceutical Corporation Management to Meet With Shareholders 8:30a ET November 7, 2011 (GlobeNewswire) Timothy R. Wright, Chairman and Interim Chief Executive Officer of Curaxis Pharmaceutical Corporation (“Curaxis” or the “Company`) (OTCQB:CURX), announced today that the new management team and newly installed board of directors (the “Board”) will be meeting with the Company`s shareholders this week. The Company has scheduled its annual shareholders` meeting to be held in Cary, North Carolina on Tuesday, November 8, 2011. Not only is this the first shareholders` meeting for the Company but it is also the first opportunity for the Board to meet with its shareholder base.
On June 27, 2011, the Company announced changes to the Board and its executive management team to better position the Company for its next phase of growth and development. Specifically, two executive officers and co-founders of the Company resigned along with three independent directors. Six new directors were appointed to the Board and Mr. Wright was appointed as the Interim Chief Executive Officer. The new Board has a wealth of experience and comprehensive knowledge of life sciences, operations and strategic management in the area of pharmaceuticals. In addition, the newly appointed Board members have significant experience in the necessary industry arenas to execute the Company`s business plan on an accelerated basis.
Mr. Wright commented, saying, “Aside from dealing with transitional items, the new leadership team has been working diligently since June on advancing the Company`s therapeutic platform in clinical trials and firming up our intellectual property position. We believe that a partner company with neuroscience depth could leverage and capitalize on our existing and completed preclinical and clinical work in Alzheimer`s. Our efforts are focused on finding a strong development partner. Alzheimer`s disease continues to be one of the world`s largest unmet medical needs and we are optimistic that our therapeutic platform could modify the progression of the disease in diagnosed patients and also complement current symptomatic treatments available.” About Curaxis Pharmaceutical Corporation Curaxis is an emerging specialty pharmaceutical company with a hormone drug product candidate for the treatment of Alzheimer`s disease and multiple cancers. Curaxis` therapeutic platform is based on the hypothesis that many diseases of aging may be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a hormonal endocrine feedback loop that controls development, reproduction and aging in animals.
This drug development platform is built on the premise that hormones associated with this feedback loop are beneficial early in life, when they promote growth and development, but are harmful later in life when the mechanism for feedback is compromised, thereby leading to disease processes, including pathologies associated with Alzheimer`s disease.
——————————————————————– Follow SR&R on:
[2][jpeg] [3][jpeg] *To make sure you receive email alerts, please add [4]alerts@stockrockandroll.com to your email`s contact list.
——————————————————————————- ———————————————————————- DISCLAIMER:
This report/release/advertisement is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: StockRockandRoll.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. StockRockandRoll.com does not provide trading, investment or tax advice, and readers shall not rely on statements by StockRockandRoll.com employees which purport to provide such advice. Full disclaimer can be read at http://www.StockRockandRoll.com/Disclaimer/
Release of Liability: Through use of this website viewing or using you agree to hold StockRockandRoll.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. StockRockandRoll.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockRockandRoll.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead StockRockandRoll.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. StockRockandRoll is compliant with the Can Spam Act of 2003. StockRockandRoll.com does not offer such advice or analysis, and StockRockandRoll.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk.
It is possible that an investor`s investment may be lost or impaired due to the speculative nature of the companies profiled.
StockRockandRoll.com has been compensated fifteen-thousand dollars for this one-day profile on CURX by Equities Awareness Group, LLC..
StockRockandRoll.com owns no shares of CURX, nor plans on buying any in the future. A third party may have shares and may liquidate it which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company.
All direct and third party compensation received will be disclosed within each individual email in accordance with section 17(b) of the 1 9 3 3 Securities Act. Any compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies.
StockRockandRoll.com has not investigated the background of the third party, the hiring company. Anyone viewing our website and advertisement should assume that the hiring party and affiliates of the hiring party own shares of the profiled company of which they plan to liquidate, further understanding that the liquidation of those shares will most likely impact the share price of the profiled company negatively. StockRockandRoll.com affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the share price of the security.
The Private Securities Litigation Reform Act of 1995 provides investors a `safe harbor` in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks an uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, StockRockandRoll.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, StockRockandRoll.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. StockRockandRoll.com is not responsible for any claims made by the companies advertised herein, nor is StockRockandRoll.com responsible for any other promotional firm, its program or its structure.
——————————————————————————- ——————————————————————- StockRockandRoll 2011 References 1. http://www.StockRockandRoll.com/
2. http://www.twitter.com/stockrocknroll 3. http://www.facebook.com/StockRockandRoll 4. mailto:alerts@stockrockandroll.com This message was sent to from:
Stock Rock and Roll | 110 Main Street | Newark, nj 07102
Related posts:
- Breakout Pharmaceutical Play- Could CURX be the Next VRML?
- CURX-_a_Cure_for_Alzheimer’s_Disease_may_not_be_to_far_